Progress in ERX-315 Phase 1 Clinical Trial

Innovative cancer therapy demonstrates favorable safety profile — Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that the first patient has been…

Etira Expands Clinical Trial Sites

Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South…

Research on Etira drugs win awards at AACR 2025

Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…

Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025

Chicago, IL - April 23, 2025: Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…

Second site activated for ERX-315 trial

Adelaide, Australia – March 17, 2025:  Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research…

ERX-315 Phase 1 Clinical Trial Update

Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…

Dr. Raj appointed as Etira Chief Medical Officer

Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…

First patient dosed in ERX-315-101 Clinical Trial

Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC)  in Sydney, Australia.…

Drs. Jenkins and Stebbing join Etira Board

Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…

Validation of ERX-208 in Ovarian Cancer

Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…